All News
Complex Evolution of RA Management and Outcomes
FIRST is a Japanese longitudinal, real world, registry of rheumatoid arthritis (RA) management and over the las 20 years has shown significantly improved outcomes, yet significant challenges and unmet needs remain.
Read Article
EULAR Guidelines on Reproductive Health
d
MedPage Today
- Many rheumatologic conditions such as rheumatoid arthritis and lupus often strike women during their reproductive years, with drugs being the primary therapies.
- Experts assembled by EULAR determined that most of the common medi
FDA Approves Rinvoq for Giant Cell Arteritis
Based on the results of the SELECT-GCA study, the US FDA has approved upadacitinib (Rinvoq or UPA) for the treatment of adults with giant cell arteritis (GCA), also known as temporal arteritis. This is the 9th FDA approved indication for upadacitinib in the U.S. for use in rheumatology, gastroenterology, and dermatology.
Read Article
Delayed diagnosis in RA can lead to joint damage and long-term disability. 14-3-3eta offers added value when RF and anti-CCP are negative. Dr. @WalterMaks shares how this biomarker supports earlier detection and ongoing care. Sponsored by Augurex. Full post: https://t.co/vp5hY4LCdw
Dr. John Cush RheumNow ( View Tweet)
Immune Checkpoint Inhib causing Myasthenia Gravis w/ poor outcomes - 16 ICI Rx pts (9 Lung CA, 7 other tumors) Dx w/ MG; 11 w/ overlap myositis. Mean onset @ 49d. All Rx wp steroids, 6 immunosuppressives, 5 plasma exchange; only 2 complete resp. 6 deaths re: MG complications https://t.co/PUc6kIE7FW
Dr. John Cush RheumNow ( View Tweet)
🔓 Unlock the latest in lupus care!
RheumNow presents Lupus Unlocked – Keys to Mastery, a month-long dive into clinical insights and expert perspectives.
KOL videos & articles
Tuesday Nite Rheumatology Webinars
Weekly Podcasts
Surveys + Downloadable Slides
📅 Launching May 1 – https://t.co/WhihzdLxIJ
Dr. John Cush RheumNow ( View Tweet)
An IL-23i in PsA: Maintenance of treatment response through ~4 years in Phase 3 studies
Discover the post hoc analysis presented at the Fall 2024 Clinical Dermatology Conference in the poster hall. Sponsored by AbbVie Medical Affairs + Health Impact.
https://t.co/qq5Z4SgKv5 https://t.co/VIt9GidyZ3
Dr. John Cush RheumNow ( View Tweet)
Study of 104 RA-ILD pts found that (31.7%) RA-ILD patients were ANCA positive (29/31 were p-ANCA+). compared to ANCA neg, ANCA+ RA-ILD had more respiratory Sxs, ANA positivity, worse PFTs, more acute exacerbations of ILD, more bronchietasis & honeycombing https://t.co/vZODUW9tSX https://t.co/zTrdtcc78O
Dr. John Cush RheumNow ( View Tweet)
Neglected adult PFAPA syndrome case ub 69 yoF mis-Dx as pharyngitis or lymphadenitis unresponsive to Abx. Could've been Rx w/ daily colchicine. (PFAPA = Periodic Fever, Aphthous stomatitis, Pharyngitis and cervical Adenitis) https://t.co/0Nx5uFlwSx https://t.co/ZAUILEsH8E
Links:
Dr. John Cush RheumNow ( View Tweet)
Norwegian RevNatus Pregnancy study on 417 births in 350 women w/ axSpA: 86% (347) were breastfeeding @6wks, 70% @6mos, & 38% @12 mos. Non-breastfeeders more likely to have C-section (41 vs 20%), higher ASDAS-CRP (2.6 vs 2.2), CRP (5.3 vs 3.3), & VAS pain (41 vs 32) https://t.co/DI6owL5dof
Dr. John Cush RheumNow ( View Tweet)
Osteoarthritis Initiative (OAI) longitudinal study analyzed 1075 #OA knees (1/pt) in 96 mo. MRI study to predict outcomes. Infrapatellar fat pad (IPFP volume & signal) predicted future knee replacement & long-term damage. IPFP correlated w/ cartil. volume & BM lesions; Not Sxs. https://t.co/Xsju7JdEVE
Dr. John Cush RheumNow ( View Tweet)
Rheumatology: Believe It or Not (4/25/2025)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow. Should we believe the reviews and metanalyses?
https://t.co/pJFhcBkvjO https://t.co/9evGknrMSo
Dr. John Cush RheumNow ( View Tweet)
RHEUMATOLOGIST SURVEY: Which Lupus patients should undergo renal Bx?
Dr. John Cush RheumNow ( View Tweet)
RHEUMATOLOGIST Survey: What are your contraindications tor renal Bx?
Dr. John Cush RheumNow ( View Tweet)
Gout pts No-Shows after ED: Study of 159 gout pts w/ gout flare & ED visit - only 56 (35%) had an outpatient visit addressing gout within 6 mos. Higher odds w/ being married (OR 2.66), no comorbidities (OR 3.86), colchicine use (OR 2.7), being older (OR 1.44) https://t.co/tAorjwf8xX
Dr. John Cush RheumNow ( View Tweet)
US- Top Drug Rx Sales in 2024
Semaglutide $54 Billion
Tirzepatide $31.7 B
Adalimumab $28B
Apixaban $26 B
Empagliflozin $20.5 B
Pembrolizumab $18 B
Ustekinumab $17 B
Risankizumab $16 B
Dupilumab $15.6 B
Etanercept $10.1 B
Secukinumab $7.7 B
Immune globulin $7.1 B
Upadacitinib $7 https://t.co/Wjcu7LrTfC
Dr. John Cush RheumNow ( View Tweet)
RHEUMATOLOGIST SURVEY: Which Lupus patients should undergo renal Bx?
Dr. John Cush RheumNow ( View Tweet)
RHEUMATOLOGIST Survey: What are your contraindications tor renal Bx?
Dr. John Cush RheumNow ( View Tweet)
U.S. healthcare pharmaceutical spending reached $805.9 billion in 2024, a 10.2% increase from 2023 https://t.co/Aq7utEJ8sK https://t.co/zgEPppe6Oe
Dr. John Cush RheumNow ( View Tweet)
Review of SARCOPENIA - a loss of muscle mass and function, with significant implications on physical performance. More common in RA, SSc, SpA, SLE, FM, myositis, and vasculitis https://t.co/tCXdoEn9xR https://t.co/PvtmVCv2QJ
Dr. John Cush RheumNow ( View Tweet)